Lakeside Holding Ltd
For the period ended Sep 30, 2025. Filed Nov 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 19, 2025
QNME$0.37+9.0%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and June 30, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
** AS OF SEPTEMBER 30, 2025 (UNAUDITED) AND JUNE 30, 2025**
| As of September 30, 2025 (unaudited) | As of June 30, 2025 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $4,539,636 | $4,956,060 |
| Accounts receivable – third parties, net of credit loss allowance of $171,613 and $87,728 | 3,091,279 | 2,895,580 |
| Accounts receivable – related party, net of credit loss allowance of $nil and $nil | 352,896 | 396,331 |
| Note receivable | 13,873 | 65,152 |
| Prepayment, deposit and other receivable – third parties | 4,948,382 | 449,977 |
| Other receivable – related party | 1,146,844 | 869,430 |
| Contract assets | 49,392 | 119,054 |
| Inventories, net | 131,986 | 96,534 |
| Right of return asset | 80,554 | 141,687 |
| Loan receivable from related parties | 386,541 | 277,741 |
| Loan receivable from a third party | 253,107 | 11,380 |
| Total current assets | 14,994,490 | 10,278,926 |
| NON-CURRENT ASSETS | ||
| Long- term investment | 15,741 | 15,741 |
| Property and equipment at cost, net of accumulated depreciation | 409,393 | 389,421 |
| Intangible assets, net | 344,069 | 365,440 |
| Right of use operating lease assets | 2,687,972 | 3,158,202 |
| Right of use financing lease assets | 85,197 | 93,797 |
| Deposit and prepayment | 98,327 | 103,934 |
| Total non-current assets | 3,640,699 | 4,126,535 |
| TOTAL ASSETS | $18,635,189 | $14,405,461 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payables – third parties | $2,539,331 | $2,494,217 |
| Accounts payables – related parties | 104,682 | 65,237 |
| Accrued liabilities and other payables | 2,157,881 | 2,119,994 |
| Current portion of obligations under operating leases | 1,593,788 | 2,323,290 |
| Current portion of obligations under financing leases | 44,968 | 47,035 |
| Loans payable, current | 2,271,368 | 1,300,112 |
| Contract liabilities | 33,530 | 15,355 |
| Tax payable | 358,607 | 312,903 |
| Due to shareholders | 142,826 | - |
| Due to a related party | 260,144 | - |
| Convertible debts - current | 133,198 | 910,675 |
| Refund liabilities | 198,806 | 77,235 |
| Total current liabilities | 9,839,129 | 9,666,053 |
| NON-CURRENT LIABILITIES | ||
| Loans payable, non-current | 147,735 | 60,398 |
| Loan payable to a related party | 124,176 | 124,176 |
| Deferred tax liabilities | 61,111 | 83,100 |
| Obligations under operating leases, non-current | 1,448,459 | 1,559,782 |
| Obligations under financing leases, non-current | 60,249 | 66,267 |
| Total non-current liabilities | 1,841,730 | 1,893,723 |
| TOTAL LIABILITIES | $11,680,859 | $11,559,776 |
| Commitments and Contingencies | ||
| EQUITY | ||
| Common stocks, $0.0001 par value, 200,000,000 shares authorized, 17,427,559 and 10,500,000 issued and outstanding as of September 30, 2025 and June 30, 2025, respectively | 1,743 | 1,050 |
| Additional paid-in capital | 13,512,515 | 8,084,275 |
| Statutory reserve | 74,608 | 63,416 |
| Deficits | (6,683,779) | (5,315,371) |
| Accumulated other comprehensive income | 49,243 | 12,315 |
| Total equity | 6,954,330 | 2,845,685 |
| TOTAL LIABILITIES AND EQUITY | $18,635,189 | $14,405,461 |
CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)
AND COMPREHENSIVE INCOME (LOSS)
FOR THE PERIODS ENDED SEPTEMBER 30, 2025 AND 2024
| For The Three Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue from cross-border freight solutions – third party | $4,181,714 | $3,599,787 |
| Revenue from cross-border freight solutions – related parties | 580,160 | 481,767 |
| Revenue from distribution of pharmaceutical products – third parties | 1,338,015 | - |
| Total revenue | 6,099,889 | 4,081,554 |
| Cost of revenue from cross-border freight solutions – third party | 3,733,846 | 2,994,285 |
| Cost of revenue from cross-border freight solutions – related party | 466,506 | 564,730 |
| Cost of revenue from pharmaceutical products – third parties | 790,770 | - |
| Total cost of revenue | 4,991,122 | 3,559,015 |
| Gross profit | 1,108,767 | 522,539 |
| Operating expenses: | ||
| Selling expenses | 189,411 | - |
| General and administrative expenses | 2,107,655 | 1,837,206 |
| Provision of allowance for expected credit loss | 83,325 | 12,837 |
| Total operating expenses | 2,380,391 | 1,850,043 |
| Loss from operations | (1,271,624) | (1,327,504) |
| Other income (expense) | ||
| Other income, net | 146,839 | 109,788 |
| Interest expense | (196,441) | (28,110) |
| Total other (expense) income | (49,602) | 81,678 |
| Loss before income taxes | (1,321,226) | (1,245,826) |
| Income tax expense | 35,990 | 89,581 |
| Net loss | (1,357,216) | (1,335,407) |
| Other comprehensive (loss) income: | ||
| Foreign currency translation gain | 36,928 | 12,993 |
| Comprehensive loss | $(1,320,288) | $(1,322,414) |
| Loss per share – basic and diluted | $(0.09) | $(0.18) |
| Weighted Average Shares Outstanding – basic and diluted | 14,733,489 | 7,500,000 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
| Common Shares | Amount | Subscription Receivable | Additional Paid in Capital | Deficits | Accumulated Other Comprehensive Income | Total | |
|---|---|---|---|---|---|---|---|
| Balance at June 30, 2024 | 6,000,000 | $600 | $(600) | $642,639 | $(5,819) | $2,972 | $639,792 |
| Paid in capital | — | — | 600 | — | — | — | 600 |
| Net loss for the three months ended September 30, 2024 | — | — | — | — | (1,335,407) | — | (1,335,407) |
| Initial public offering, net of share issuance costs | 1,500,000 | 150 | — | 4,300,152 | — | — | 4,300,302 |
| Foreign currency translation adjustment | — | — | — | — | — | 12,993 | 12,993 |
| Balance at September 30, 2024 | 7,500,000 | $750 | $— | $4,942,791 | $(1,341,226) | $15,965 | $3,618,280 |
| Common Shares | Amount | Additional Paid in Capital | Deficits | Accumulated Other Comprehensive Income | Statutory Reserves | Total | |
|---|---|---|---|---|---|---|---|
| Balance at June 30, 2025 | 10,500,000 | $1,050 | $8,084,275 | $(5,315,371) | $12,315 | $63,416 | $2,845,685 |
| Net loss for the three months ended September 30, 2025 | — | — | — | (1,357,216) | — | — | (1,357,216) |
| Statutory reserve | — | — | — | (11,192) | — | 11,192 | — |
| Foreign currency translation gain | — | — | — | — | 36,928 | — | 36,928 |
| Common stock issued for consulting services | 2,300,000 | 230 | 1,915,970 | — | — | — | 1,916,200 |
| Issuance of common shares upon exercise of Convertible note | 820,330 | 82 | 512,651 | — | — | — | 512,733 |
| Issuance of common shares - Private placement | 3,807,229 | 381 | 2,999,619 | — | — | — | 3,000,000 |
| Balance at September 30, 2025 | 17,427,559 | $1,743 | $13,512,515 | $(6,683,779) | $49,243 | $74,608 | $6,954,330 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.